NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Price Target & More

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.19. The biotechnology company earned $4.85 million during the quarter, compared to analysts' expectations of $15.63 million. Momenta Pharmaceuticals had a negative net margin of 88.77% and a negative return on equity of 28.56%. The firm's revenue for the quarter was down 81.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.46) EPS. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Momenta Pharmaceuticals.

8 analysts have issued 1-year price targets for Momenta Pharmaceuticals' shares. Their forecasts range from $6.00 to $24.00. On average, they anticipate Momenta Pharmaceuticals' share price to reach $15.6250 in the next twelve months. This suggests that the stock has a possible downside of 48.5%. View Analyst Ratings for Momenta Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Momenta Pharmaceuticals include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), argenx (ARGX), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Acceleron Pharma (XLRN) and Repligen (RGEN).

Press coverage about MNTA stock has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Momenta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.12%), Bank of Montreal Can (0.06%), Whittier Trust Co. (0.06%), Municipal Employees Retirement System of Michigan (0.03%) and Amalgamated Bank (0.02%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, Richard P Shea, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

MNTA stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Santiago Arroyo, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

MNTA stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Whittier Trust Co. and Amalgamated Bank. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MNTA stock can currently be purchased for approximately $30.35.

Momenta Pharmaceuticals has a market capitalization of $2.35 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]